# DESCRIPTION

## FIELD OF THE INVENTION

- define field of invention

## BACKGROUND OF THE INVENTION

- introduce epithelial ovarian cancer
- describe current treatment options
- discuss epigenetic regulation
- introduce SWI/SNF complex
- describe CARM1 gene amplification
- discuss Polycomb-repressive complex 2 (PRC2)
- introduce EZH2 inhibitors
- summarize current research

## SUMMARY OF THE INVENTION

- introduce method of treating cancer
- specify cancer type
- specify EZH2 inhibitor
- specify cancer type
- specify cancer type
- specify cancer type
- specify EZH2 inhibitor
- specify overexpression level
- introduce combination therapy
- specify platinum drug
- introduce pharmaceutical composition

## DETAILED DESCRIPTION OF THE INVENTION

- define terms used in the invention

### Definitions

- define co-administration
- define active pharmaceutical ingredient
- define effective amount
- define therapeutic effect
- define pharmaceutically acceptable salt
- define prodrug
- define isotopically enriched atoms
- define ranges
- define about
- define comprising
- define crystalline and amorphous forms
- define polymorphs
- define solvates
- define hydrates
- define unsolvated polymorphs
- define conformational polymorphs
- define amorphous forms

### Methods of Treating Cancers and Other Diseases

- describe method for treating diseases
- describe treating hyperproliferative disorders
- describe treating cancer
- describe treating EZH2-mutated cancer
- describe testing efficacy of compounds
- describe models for determining efficacy
- describe specific models for various cancers

### EZH2 Inhibitors

- describe method of treating cancer with EZH2 inhibitor
- describe administering EZH2 inhibitor with platinum-based drug
- describe EZH2 inhibitor GSK126
- describe EZH2 inhibitor GSK503
- describe EZH2 inhibitor GSK343
- describe EZH2 inhibitor tazemetostat
- describe EZH2 inhibitor CPI-169
- describe EZH2 inhibitor EPZ-5687
- describe EZH2 inhibitor EPZ-11989
- describe EZH2 inhibitor UNC-1999
- describe EZH2 inhibitor El1
- describe EZH2 inhibitor DZNep
- describe EZH2 inhibitor sinefungin

### Platinum-Based Antineoplastic Drugs

- introduce platinum-based antineoplastic drugs
- list examples of platinum-based antineoplastic drugs
- describe cisplatin
- describe carboplatin
- describe oxaliplatin
- describe satraplatin
- describe picoplatin
- describe nedaplatin
- describe triplatin and lipoplatin

### Pharmaceutical Compositions

- provide pharmaceutical composition
- specify concentration of active pharmaceutical ingredients
- specify concentration range of active pharmaceutical ingredients
- specify amount of active pharmaceutical ingredients
- specify amount range of active pharmaceutical ingredients
- describe effective dosage range
- specify molar ratio of active pharmaceutical ingredients
- specify weight ratio of active pharmaceutical ingredients
- describe treatment of cancers associated with CARM1
- list specific cancers associated with CARM1
- introduce pharmaceutical compositions for oral administration
- describe solid pharmaceutical composition for oral administration
- describe liquid pharmaceutical composition for oral administration
- list forms of pharmaceutical compositions for oral administration
- describe preparation of pharmaceutical compositions for oral administration
- describe compressed tablets
- describe molded tablets
- introduce pharmaceutical compositions for injection
- describe pharmaceutical composition for injection
- list forms of pharmaceutical compositions for injection
- describe aqueous solutions for injection
- describe non-aqueous solutions for injection
- describe prevention of microbial action
- conclude pharmaceutical compositions
- define pharmaceutical compositions
- describe sterile injectable solutions
- describe dispersions
- describe powder preparation methods
- introduce pharmaceutical compositions for topical delivery
- describe transdermal delivery formulations
- describe carriers and excipients
- describe penetration-enhancing molecules
- describe transdermal patches
- describe patch construction and use
- introduce pharmaceutical compositions for inhalation
- describe inhalation formulations
- describe nebulization methods
- describe dry powder inhalers
- introduce other pharmaceutical compositions
- describe sublingual, buccal, rectal, intraosseous, intraocular, intranasal, epidural, or intrasp
- describe administration methods
- describe impregnated or coated devices
- describe stent delivery methods
- describe matrix materials
- describe compound application methods
- describe covalent linking methods
- describe parenteral administration forms
- introduce kits
- describe kit components
- describe kit uses
- describe kit embodiments

### Dosages and Dosing Regimens

- define dosage range
- specify dosage units
- describe single dose administration
- describe multiple dose administration
- specify dosing frequency
- describe chronic administration
- provide dosage ranges in mg
- provide dosage ranges in mg/kg
- specify effective dosages in mg
- specify effective dosages in mg/kg
- describe administration routes
- describe administration schedules
- provide dosage ranges for combination therapy
- specify dosing regimens for BID administration
- describe flexibility in dosage levels
- summarize administration modes

## EXAMPLES

- illustrate embodiments

### Example 1—CARM1 is Associated with Poor Prognosis in Ovarian Cancer Patients

- associate CARM1 with poor prognosis

### Example 2—CARM1-Expressing Cells are Sensitive to the EZH2 Inhibitor GSK126

- illustrate CARM1 expression
- demonstrate sensitivity to GSK126

### Example 3—CARM1 Depletion Abrogates GSK126 Sensitivity in CARM1-Expressing Cells

- confirm CARM1-EZH2 relationship

### Example 4—CARM1-Expressing Ovarian Cancer Depends on the Histone Methyltransferase EZH2 Activity

- introduce CARM1-expressing ovarian cancer
- show EZH2 inhibition selectivity
- describe high CARM1 expression correlation
- detail xenograft models and survival improvement
- explain CARM1-dependent EZH2 target gene upregulation
- describe CARM1 promotion of EZH2-dependent gene silencing
- summarize therapeutic strategy for CARM1-expressing cancers
- introduce cell lines and culture conditions
- describe reagents and antibodies used
- detail CRISPR-mediated CARM1 knockout
- explain lentivirus and retrovirus infection
- describe reverse-transcriptase quantitative PCR (RT-qPCR)
- detail Annexin V assay
- describe 3D Matrigel assays
- explain colony formation assay
- introduce intrabursal orthotopic xenograft models in vivo
- describe subcutaneous xenograft models in vivo
- detail epigenetic targeting small molecule set screen
- explain RNA sequencing (RNA-Seq) and chromatin immunoprecipitation followed by sequencing (ChIP-Seq)
- describe chromatin immunoprecipitation (ChIP)
- perform ChIP
- analyze ChIP DNA
- perform bioinformatics analysis
- align RNA-seq data
- estimate raw read counts and RPKM
- estimate significance of differential expression
- analyze ChIP-seq data
- call significant peaks
- overlap genes with significantly decreased peaks
- perform gene set enrichment analysis
- analyze TCGA data
- test for negative association with CARM1 expression
- perform statistical analysis
- analyze high-throughput genetic profiles
- express CARM1 in EOC
- correlate CARM1 amplification with poor survival
- generate CARM1 knockout clone
- evaluate epigenetic inhibitors
- analyze EZH2 inhibitors
- introduce CARM1-expressing ovarian cancer
- perform RNA-deep sequencing and ChIP-seq analysis
- identify direct EZH2 target genes regulated by CARM1
- cross-reference RNA-seq and ChIP-seq data
- identify genes negatively correlated with CARM1 expression
- perform pathway analysis
- identify tumor suppressors regulated by CARM1 and EZH2
- perform Ingenuity Pathway Analysis
- identify upstream transcription regulator SMARCA4
- discuss antagonistic regulation of genes by EZH2 and SWI/SNF complexes
- validate identified genes regulated by CARM1 and EZH2
- perform ChIP analysis
- validate association of EZH2 and H3K27Me3 with gene loci
- discuss switch from EZH2 to unmethylated BAF155
- validate association of RNA polymerase II with gene loci
- discuss regulation of CARM1-regulated BAF155Me target genes
- test effects of CARM1-mediated BAF155 methylation
- replace endogenous BAF155 with mutant or wild-type BAF155
- validate association of BAF155 with EZH2/BAF155 target genes
- discuss regulation of antagonism between SWI/SNF and PRC2
- test EZH2 inhibitor GSK126 in vivo
- perform subcutaneous and orthotopic xenograft models
- validate suppression of tumor growth by GSK126
- perform immunohistochemical analysis
- validate correlation of molecular pathways with tumor growth suppression
- discuss dependence of CARM1-expressing cells on EZH2 activity
- discuss regulation of antagonism between EZH2 and BAF155
- discuss context-dependent role of CARM1 in cancer
- discuss therapeutic implications of targeting EZH2 activity

